Cite this: *Chem. Sci.*, 2020, **11**, 3903

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 22nd February 2020
Accepted 20th March 2020

DOI: 10.1039/d0sc01060j

rsc.li/chemical-science

Steric and stereoscopic disulfide construction for cross-linkage *via* *N*-dithiophthalimides†‡

Wen-Chao Gao,^a Jun Tian,^b Yu-Zhu Shang^b and Xuefeng Jiang^{a*}

Disulfide bonds are a significant motif in life and drug-delivery systems. In particular, steric hindrance and stereoscopic disulfide linkers are closely associated with the stability of antibody–drug conjugates, which affects the potency, selectivity, and pharmacokinetics of drugs. However, limited availability and diversity of tertiary thiols impede the construction of steric and stereoscopic disulfides for cross-linkage in biochemistry and pharmaceuticals. Through modulating the mask effect of disulfurating reagents, we develop a facile and robust strategy for construction of diverse steric and stereoscopic disulfides *via* *N*-dithiophthalimides. The practical cross-linkage of biomolecules including amino acids, saccharides, and nucleosides with different drugs and fluorescent molecules is successfully established through hindered disulfide linkers.

Introduction

Development of targeted delivery conjugates, such as antibody–drug conjugates (ADCs)^{1,2} and small molecule–drug conjugates (SMDCs),³ has become a promising direction in modern drug development. The nature of linkers between targeting moieties and drugs plays the key role in the therapeutic efficacy of drug conjugates.⁴ As a commonly used linker, disulfides can be cleaved *via* an intracellular thiol-redox process for procedural drug release.⁵ Thus, surroundings of disulfide linkers significantly affect the potency, selectivity, and pharmacokinetics of conjugates.^{6,7} Due to the embedded cavity and chiral environment in cellular redox systems, the stability of disulfide linkers mainly relies on the adjacent steric and stereoscopic effects (Scheme 1a).⁸ Clinically approved antibody–drug conjugates such as Mylotarg and Besponsa demonstrated that *gem*-dimethyl-hindered disulfide linkers enhanced the stability of conjugates in internal circulation and the selectivity of payload delivery in cytosol.² Furthermore, these effects were found in anti-cancer natural products⁹ and peptides¹⁰ for the expression of cytotoxicity and receptor-selectivity as well.^{11,12} Therefore, efficient construction of steric and stereoscopic disulfides for molecule cross-

linkage is urgently demanded. Although substitution of tertiary thiols with preactivated *S*-partners is conventionally employed for the synthesis of steric disulfides (Scheme 1b),¹³ adjacent variation of hindrance, stereocenter construction and molecule-cross-linkage remain underdeveloped.

Direct disulfuration *via* designed disulfurating reagents has become a better choice due to their straightforward facility for unsymmetrical disulfide and late-stage modification. To meet diverse requirements, masked disulfurating reagents (RSSAc and RSSOMe) were developed by us to incorporate RSS moieties into multifarious systems (Scheme 1c).^{14,15} Considering the great importance of steric and stereoscopic disulfides, we are intrigued by disulfuration of α -branched esters to access diverse hindered disulfides. Nevertheless, steric hindrance of α -branched esters is the first barrier for disulfuration. Furthermore, due to the flexibility and volatility of disulfuryl groups¹⁶ and the relatively longer distance between substituents on disulfides and the adjacent carbon center, three-dimensional induction of disulfides is confronted with great challenge. We envisage that disulfurating reagents, *N*-dithiophthalimides with “soft” mask phthalimide,^{17–19} enable the facilitation of the disulfuration of branched soft nucleophiles based on the hard and soft acid and base (HSAB) model.²⁰ Moreover, the carbonyl groups from imide are capable of serving as H-bonding donors to assist the chiral induction.²¹ Herein, we disclose a straightforward disulfurating strategy for construction of steric and stereoscopic disulfides *via* *N*-dithiophthalimides, which is a splendid cross-linkage of various functional molecules for molecule hybrids (Scheme 1d).

Results and discussion

Collective *N*-phthalimide-based sulfurating reagent library

Although successful protocols for *N*-dithiophthalimide (PhthSSR) synthesis have been reported,^{18,19} moisture-sensitive

^aShanghai Key Laboratory of Green Chemistry and Chemical Process, Department of Chemistry, East China Normal University, Shanghai, 200062, P. R. China. E-mail: xjiang@chem.ecnu.edu.cn

^bCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, P. R. China

^cState Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Shanghai, 200032, P. R. China

† Dedicated to Prof. Eric Block for his 78th birthday.

‡ Electronic supplementary information (ESI) available: Experimental procedure, crystal data, and copies of NMR and HPLC spectra. CCDC 1975995–1975997. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d0sc01060j

Scheme 1 (a) Significance of steric and stereoscopic disulfides. (b) Substitution of tertiary thiol. (c) Disulfuration via mask strategy. (d) Disulfuration for steric and stereoscopic disulfide construction.

PhthSCL makes scalable preparation and application burdensome. A revised protocol affords a solid scale-up procedure: pretreatment of thiols with *N,N'*-thiobisphthalimide (1.5 equiv.) in 1,2-dichloroethane at 80 °C afforded PhthSSR (**1**) in moderate to excellent yields on a 2–3 mmol scale (Table 1). The structure of phthalimide-based disulfurating reagents was further confirmed by the X-ray analysis of **1a**. A variety of aromatic substituents, including electron-donating and -withdrawing groups on the phenyl ring (**1a** and **1b**), naphthyl (**1c** and **1d**), and thienyl (**1e**) rings, were well tolerated in this reaction. Besides, diverse aliphatic disulfurating reagents including substituted benzyl (**1f** and **1g**), *tert*-butyl (**1h**), cyclohexyl (**1i**), alkenyl (**1j**) and alkynyl (**1k**) groups could be smoothly constructed. Furthermore, phthalimide-based disulfurating reagents containing cross-linking groups (carboxyl, hydroxyl, borono and hydroxysuccinimide) were successfully prepared in high yields under

the standard conditions (**1l–q**). The compatibility of various linkage-containing groups provides an excellent basis for molecule conjugation and hybridization.

Thiol-containing biomolecules such as cysteine, β -thioglycoside, and anti-hypertension drug captopril were converted to the desired disulfurating reagents in high yields (**1r–t**). Notably, all these *N*-dithiophthalimides can be stored at room temperature (25 °C) for 4–6 months without any detectable deterioration.

Sterically bulky disulfides

With the large-scale *N*-dithiophthalimide library in hand, the construction of quaternary α -disulfuryl β -keto esters was consequently explored. As shown in Table 2, disulfuration of various β -keto esters was first examined using DMAP as a catalyst. Diverse scales of ester groups were tolerated in the current

Table 1 Construction of the *N*-dithiophthalimide library^{a,b}

^a Reaction conditions: thiol (2 mmol) and *N,N'*-thiobisphthalimide (3 mmol) in ClCH₂CH₂Cl (10 mL) were stirred at 80 °C for 2–4 h.

^b Isolated yields. ^c The reaction was performed on a 10 mmol scale.

disulfuration reaction (**3a–c**), whose structure was further confirmed by the X-ray analysis of **3a**. Five-membered ring β-keto esters with electron-donating and -withdrawing groups on the phenyl ring were well compatible in this transformation affording the corresponding products in excellent yields (**3d–f**). Aliphatic cyclopentanone-derived β-keto ester was also successfully transformed into the desired product **3g** in good yield. As for the β-keto ester bearing a six-membered-ring, the product **3h** was obtained in 57% yield. Unfortunately, acyclic 1,3-dicarbonyl substrates such as 2-methyl-ethylbenzoylacetate, 3-methylpentane-2,4-dione, or 2-methyl-diethylmalonate failed to afford the desired steric disulfides. Notably, various *gem*-substituent-hindered disulfides could be readily afforded with silyl ketene acetals as nucleophiles.²² Incorporation of disulfuryls into silyl ketene acetals with spiro-rings such as spirocyclohexyl (**3i**), spirocyclopentyl (**3j**), and spirocyclobutyl (**3k**) is delightfully compatible, providing a rapid protocol for spiro-hindered disulfide synthesis. Moreover, not only *gem*-dimethyl-hindered disulfides (**3l** and **3m**), but also *gem*-diphenyl-hindered one (**3n**) could be well constructed through this disulfuration reaction in moderate yields. A broad range of *N*-dithiophthalimides, regardless of electron-donating or -withdrawing groups on the phenyl ring, efficiently transformed the disulfur motifs into the desired products (**3o–s**). Aliphatic disulfurating reagents, bearing adjacent tertiary and quaternary carbon centers (**3t** and **3u**), could be transformed into the

Table 2 Construction of diverse steric disulfides^{a,b}

^a Reaction conditions: β-keto ester (0.1 mmol), *N*-dithiophthalimide (0.12 mmol) and DMAP (0.02 mmol) in CH₂Cl₂ (1 mL) were stirred at room temperature for 12–24 h. ^b Isolated yields. ^c TMS enol ethers were used instead of the corresponding β-keto esters. ^d Reaction conditions: TMS ketene acetal (0.2 mmol), *N*-dithiophthalimide (0.4 mmol), and DMAP (0.04 mmol) in THF (2 mL) were stirred at room temperature for 8–12 h. ^e 0.1 mmol of DMAP were used.

desired disulfide products with bilateral hindrance efficiently. The successful incorporation of the allylic disulfuryl motif demonstrated the good compatibility of the C–C double bond (**3v**). Disulfides with the terminal C–C triple bond (**3w**) could be also tolerated in this transformation, enabling the further linkage *via* the click reaction.²³ Notably, free carboxyl (**3x** and **3y**) and hydroxyl (**3z**) were well compatible, which provided more chances for further molecule cross-linkage.

Sterically bulky disulfide cross-linkage

To further demonstrate the practicality of the present method, steric disulfides were comprehensively applied for molecule hybridization (Table 3).²⁴ Biomolecules such as amino acids (**5a**), dipeptides (**5b**), and β -thiosaccharides (**5c**) can be efficiently linked with β -keto esters *via* this steric disulfide. The anti-cancer drug podophyllotoxin (**5d**), antioxidation natural product δ -tocopherol (**5e**), and molecule probe fluorescein (**5f**) were efficiently linked with β -keto esters through one-pot disulfuration and esterification. Hybridization of diverse amino acids (**5g**), amino acid with fluorescent molecules (**5h**), amino acid with saccharide (**5i**), and amino acid with nucleoside (**5j**) was all successfully established, providing possibilities to modify protein structures, improve pharmacological efficacy and overcome drug resistance.^{25,26} Non-steroidal anti-inflammatory drug indomethacin could be successfully cross-linked with antimalarial drug artesunate (**5k**) and anti-cancer

drug podophyllotoxin (**5l**), which may serve as a dual-mode for the treatment of diseases.

Stereoscopic disulfide construction

To create the three-dimensional environment for discrimination and recognition of biomolecules, construction of stereoscopic disulfides was subsequently explored. The strong coordinating properties of unstable disulfuryl groups obstruct the chiral induction with metal catalysts.²⁷ Considering the existence of H-bonding acceptors in both β -keto esters and *N*-phthalimides,²⁸ chiral organic molecules based on cinchona alkaloids were tested as a catalyst for the desired enantioselective induction.^{29,30} The best result was obtained when the disulfuration was performed in dimethoxyethane (DME) with (DHQD)₂PHAL as a catalyst (Table 4).³¹ Both aromatic and aliphatic disulfur motifs could be transformed into the desired disulfides in high yields with good to excellent

Table 3 Functional molecules cross-linked *via* hindered disulfides^{a,b}

^a Conditions: **1** (0.1 mmol), **2a** (0.1 mmol), and DMAP (1.1 equiv.) in CH_2Cl_2 (2 mL) were stirred at room temperature for 12 h; then **4** (1 equiv.), HOBT (1.5 equiv.), EDCI (1.5 equiv.) and DIPEA (2.5 equiv.) were added, and the mixture was stirred at room temperature overnight. ^b Isolated yields.

^c Conditions: **1s** (0.12 mmol), **2a** (0.1 mmol) and DMAP (0.02 mmol) in CH_2Cl_2 (1 mL) were stirred at room temperature for 12 h.

Table 4 Catalytic enantioselective construction of quaternary α -disulfuryl β -keto esters^{a,b}

^a Reaction conditions: β -keto ester (1.0 equiv.), *N*-dithiophthalimide (1.2 equiv.), and (DHQD)₂PHAL (20 mol%), in 0.05 M DME solution at 25 °C for 24 h. ^b After recrystallization once.

enantioselectivities (6a–f). Notably, the enantiomeric excess of 6c could be improved to 98% after recrystallization once. The absolute configuration *R* of the stereogenic carbon center in disulfuryl products was determined by X-ray crystal structure analysis of the optically active product 6d.

Conclusions

In summary, an efficiently and generally applicable protocol for the construction of steric and stereoscopic disulfides has been developed *via* disulfuration of α -branched esters with *N*-dithiophthalimides as disulfurating reagents. Steric disulfides with subtle variation of adjacent hindered groups are comprehensively accessed with high functional-group tolerance, facilitating the structural regulation of disulfuryl linkage. Enantioselective construction of stereoscopic disulfides is also realized, which can provide chiral disulfide candidates for biological recognition. With design and synthesis of steric disulfide linkers, hybridization of various biomolecules, drugs and fluorescent tags is well linked by reversibly fractured disulfides, which provides synthetic basis for mimic of life processes and pharmacological therapy. Efforts toward the drug discovery of steric and stereoscopic disulfides are currently underway in our laboratory.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors are grateful for financial support provided by the National Key Research and Development Program of China (2017YFD0200500), NSFC (21971065, 21722202, 21672069, and 21901179 for W.-C. Gao), S&TCSM of Shanghai (Grant 18JC1415600), Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning, and the National Program for Support of Top-notch Young Professionals, China Postdoctoral Science Foundation (No. 2019M651424) and the Key R. & D. Program of Shanxi Province (No. 201803D421093).

Notes and references

- 1 R. V. J. Chari, M. L. Miller and W. C. Widdison, *Angew. Chem., Int. Ed.*, 2014, **53**, 3796–3827.
- 2 K. C. Nicolaou and S. Rigol, *Angew. Chem., Int. Ed.*, 2019, **58**, 11206–11241.
- 3 N. Krall, J. Scheuermann and D. Neri, *Angew. Chem., Int. Ed.*, 2013, **52**, 1384–1402.
- 4 K. Tsuchikama and Z. An, *Protein Cell*, 2018, **9**, 33–46.
- 5 R. Cheng, F. Feng, F. Meng, C. Deng, J. Feijen and Z. Zhong, *J. Controlled Release*, 2011, **152**, 2–12.
- 6 R. Y. Zhao, S. D. Wilhelm, C. Audette, G. Jones, B. A. Leece, A. C. Lazar, V. S. Goldmacher, R. Singh, Y. Kovtun, W. C. Widdison, J. M. Lambert and R. V. J. Chari, *J. Med. Chem.*, 2011, **54**, 3606–3623.
- 7 G. Saito, J. A. Swanson and K.-D. Lee, *Adv. Drug Delivery Rev.*, 2003, **55**, 199–215.
- 8 J. D. Sadowsky, T. H. Pillow, J. Chen, F. Fan, C. He, Y. Wang, G. Yan, H. Yao, Z. Xu, S. Martin, D. Zhang, P. Chu, J. Cruz-Chuh, A. O'Donohue, G. Li, G. D. Rosario, J. He, L. Liu, C. Ng, D. Su, G. D. L. Phillips, K. R. Kozak, S.-F. Yu, K. Xu, D. Leipold and J. Wai, *Bioconjugate Chem.*, 2017, **28**, 2086–2098.
- 9 A. Marion, M. Groll, D. H. Scharf, K. Scherlach, M. Glaser, H. Sievers, M. Schuster, C. Hertweck, A. A. Brakhage, I. Antes and E. M. Huber, *ACS Chem. Biol.*, 2017, **12**, 1874–1882.
- 10 H. I. Mosberg, R. Hurst, V. J. Hruby, K. Gee, H. I. Yamamura, J. J. Galligan and T. F. Burks, *Proc. Natl. Acad. Sci. U. S. A.*, 1983, **80**, 5871–5874.
- 11 N. Wang, P. Saidharedy and X. Jiang, *Nat. Prod. Rep.*, 2020, **37**, 246–275.
- 12 J. Zhao and X. Jiang, *Chin. Chem. Lett.*, 2018, **29**, 1079–1087.
- 13 Z. Pei, C. Chen, J. Chen, J. Cruz-Chuh, R. Delarosa, Y. Deng, A. Fourie-O'Donohue, I. Figueroa, J. Guo, W. Jin, S. C. Khojasteh, K. R. Kozak, B. Latifi, J. Lee, G. Li, E. Lin, L. Liu, J. Lu, S. Martin, C. Ng, T. Nguyen, R. Ohri, G. L. Phillips, T. H. Pillow, R. K. Rowntree, N. J. Stagg, D. Stokoe, S. Ulufatu, V. A. Verma, J. Wai, J. Wang, K. Xu,

- Z. Xu, H. Yao, S.-F. Yu, D. Zhang and P. S. Dragovich, *Mol. Pharmaceutics*, 2018, **15**, 3979–3996.
- 14 X. Xiao, M. Feng and X. Jiang, *Angew. Chem., Int. Ed.*, 2016, **55**, 14121–14125.
- 15 X. Xiao, J. Xue and X. Jiang, *Nat. Commun.*, 2018, **9**, 2191.
- 16 M. Marigo, T. C. Wabnitz, D. Fielenbach and K. A. Jørgensen, *Angew. Chem., Int. Ed.*, 2005, **44**, 794–797.
- 17 D. N. Harpp, K. Steliou and T. H. Chan, *J. Am. Chem. Soc.*, 1978, **100**, 1222–1228.
- 18 K. C. Nicolaou, R. Li, Z. Lu, E. N. Pitsinos, L. B. Alemany, M. Aujay, C. Lee, J. Sandoval and J. Gavriluk, *J. Am. Chem. Soc.*, 2018, **140**, 12120–12136.
- 19 J. Zou, J. Chen, T. Shi, Y. Hou, F. Cao, Y. Wang, X. Wang, Z. Jia, Q. Zhao and Z. Wang, *ACS Catal.*, 2019, **9**, 11426–11430.
- 20 R. G. Pearson, *J. Am. Chem. Soc.*, 1963, **85**, 3533–3539.
- 21 P. Chauhan, S. Mahajan and D. Enders, *Chem. Rev.*, 2014, **114**, 8807–8864.
- 22 M. E. Jung and G. Piizzi, *Chem. Rev.*, 2005, **105**, 1735–1766.
- 23 A. A. Kislukhin, V. P. Hong, K. E. Breitenkamp and M. G. Finn, *Bioconjugate Chem.*, 2013, **24**, 684–689.
- 24 M. Srinivasarao, C. V. Galliford and P. S. Low, *Nat. Rev. Drug Discovery*, 2015, **14**, 203–219.
- 25 A. Çapcı, M. M. Lorion, H. Wang, N. Simon, M. Leidenberger, M. C. B. Silva, D. R. M. Moreira, Y. Zhu, Y. Meng, J. Y. Chen, Y. M. Lee, O. Friedrich, B. Kappes, J. Wang, L. Ackermann and S. B. Tsogoeva, *Angew. Chem., Int. Ed.*, 2019, **58**, 13066–13079.
- 26 L. F. Tietze, H. P. Bell and S. Chandrasekhar, *Angew. Chem., Int. Ed.*, 2003, **42**, 3996–4028.
- 27 Z. Qiao, J. Wei and X. Jiang, *Org. Lett.*, 2014, **16**, 1212–1215.
- 28 T. Govender, P. I. Arvidsson, G. E. M. Maguire, H. G. Kruger and T. Naicker, *Chem. Rev.*, 2016, **116**, 9375–9437.
- 29 X. Wang, T. Yang, X. Cheng and Q. Shen, *Angew. Chem., Int. Ed.*, 2013, **52**, 12860–12864.
- 30 T. Bootwicha, X. Liu, R. Pluta, I. Atodiresei and M. Rueping, *Angew. Chem., Int. Ed.*, 2013, **52**, 12856–12859.
- 31 For details of condition optimization, see the ESI†.